Genetic counseling, testing and management of epithelial ovarian carcinoma patients: recommendations from a consensus of experts from the National Institute of Neoplastic Diseases of Peru

Abstract

The objective was to provide tools for the profiling and management of patients with epithelial ovarian cancer through genetic testing. The Consensus was made up of experts in oncology and genetics from the National Institute of Neoplastic Diseases of Peru and followed the guidelines of the Consensus Conference on Standard Operating Procedures of the European Society of Medical Oncology. The Grading of Recommendations, Assessment, Development and Evaluation (GRADE) methodology was used to assess the evidence and make recommendations. The clinical practice guidelines were graded following the Appraisal of Guidelines for Research and Evaluation instrument II (AGREE II). Genetic counseling and testing is recommended for all patients with epithelial ovarian cancer. Regardless of the findings in the tumor, germinal testing should be performed. Testing is suggested to include BRCA1, BRCA2, ATM, BRIP1, MLH1, MSH2, MSH6, PALB2, RAD51C, RAD51D, TP53, PTEN, PMS2, EPCAM and NBN. Test findings can guide pharmacological treatment. In conclusion, patients with epithelial ovarian cancer and their relatives at risk should be identified and provided with genetic counseling. The recommendations given in this consensus will be useful if they are known and implemented. Genetic counseling and testing are expected to be included in daily clinical practice.